Karen Knudsen

Summary

Publications

  1. pmc RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response
    Adam Ertel
    Kimmel Cancer Center, Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA
    Cell Cycle 9:4153-63. 2010
  2. pmc AR, the cell cycle, and prostate cancer
    Steven P Balk
    Cancer Biology Program Hematology Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Nucl Recept Signal 6:e001. 2008
  3. pmc mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer
    Matthew J Schiewer
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Endocr Relat Cancer 19:1-12. 2012
  4. pmc A tale of three PKCs: Epsilon emerges as a driver of pre-neoplastic phenotypes
    Karen E Knudsen
    Thomas Jefferson University and Kimmel Cancer Center Philadelphia, PA
    Cell Cycle 10:380-79. 2011
  5. pmc Cyclin D1 goes metabolic: Dual functions of cyclin D1 in regulating lipogenesis
    Karen E Knudsen
    Departments of Cancer Biology, Urology and Radiation Oncology Thomas Jefferson University and Kimmel Cancer Center Philadelphia, PA USA
    Cell Cycle 11:3534. 2012
  6. pmc Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer
    M J Schiewer
    Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Oncogene 28:1016-27. 2009
  7. pmc Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer
    Karen E Knudsen
    Departments of Cancer Biology, Urology, and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Clin Cancer Res 15:4792-8. 2009
  8. pmc Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
    Karen E Knudsen
    Kimmel Cancer Center, Department of Cancer Biology and Department of Urology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Trends Endocrinol Metab 21:315-24. 2010
  9. pmc Tailoring to RB: tumour suppressor status and therapeutic response
    Erik S Knudsen
    Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Nat Rev Cancer 8:714-24. 2008
  10. doi request reprint 2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways
    Supriya Shah
    Kimmel Cancer Center and Department of Cancer, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Mol Cancer Res 6:1507-20. 2008

Research Grants

Collaborators

Detail Information

Publications12

  1. pmc RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response
    Adam Ertel
    Kimmel Cancer Center, Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA
    Cell Cycle 9:4153-63. 2010
    ....
  2. pmc AR, the cell cycle, and prostate cancer
    Steven P Balk
    Cancer Biology Program Hematology Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Nucl Recept Signal 6:e001. 2008
    ..As will be discussed, discrete aberrations in this process can alter the proliferative response to androgen, and potentially subvert hormonal control of tumor progression...
  3. pmc mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer
    Matthew J Schiewer
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Endocr Relat Cancer 19:1-12. 2012
    ..Taken together, these data demonstrate that inhibition of mTOR confers a radiosensitization phenotype that is dependent on relative cell cycle kinetics and provide a foundation for clinical assessment...
  4. pmc A tale of three PKCs: Epsilon emerges as a driver of pre-neoplastic phenotypes
    Karen E Knudsen
    Thomas Jefferson University and Kimmel Cancer Center Philadelphia, PA
    Cell Cycle 10:380-79. 2011
    ..Comment on: Benavides F, et al. Cell Cycle 2011; 10:286-77:  ..
  5. pmc Cyclin D1 goes metabolic: Dual functions of cyclin D1 in regulating lipogenesis
    Karen E Knudsen
    Departments of Cancer Biology, Urology and Radiation Oncology Thomas Jefferson University and Kimmel Cancer Center Philadelphia, PA USA
    Cell Cycle 11:3534. 2012
    ..Comment on: Hanse EA, et al. Cell Cycle 2012; 11:2681-90...
  6. pmc Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer
    M J Schiewer
    Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Oncogene 28:1016-27. 2009
    ....
  7. pmc Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer
    Karen E Knudsen
    Departments of Cancer Biology, Urology, and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Clin Cancer Res 15:4792-8. 2009
    ....
  8. pmc Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
    Karen E Knudsen
    Kimmel Cancer Center, Department of Cancer Biology and Department of Urology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Trends Endocrinol Metab 21:315-24. 2010
    ..In this report, the mechanisms underlying the lethal pairing of AR deregulation and aberrant androgen synthesis in prostate cancer progression will be discussed...
  9. pmc Tailoring to RB: tumour suppressor status and therapeutic response
    Erik S Knudsen
    Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Nat Rev Cancer 8:714-24. 2008
    ..Particularly, loss of RB function is associated with differential response to wide-ranging therapeutic agents. Thus, the status of this tumour suppressor may be particularly informative in directing treatment regimens...
  10. doi request reprint 2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways
    Supriya Shah
    Kimmel Cancer Center and Department of Cancer, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Mol Cancer Res 6:1507-20. 2008
    ....
  11. pmc Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity
    Kevin A Link
    Departments of Cancer Biology and Urology, and Kimmel Cancer Center, Thomas Jefferson University College of Medicine, Philadelphia, Pennsylvania, USA
    Cancer Res 68:4551-8. 2008
    ....
  12. pmc Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer
    Clay E S Comstock
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Clin Cancer Res 15:5338-49. 2009
    ..Here, the frequency, tumor relevance, and mechanisms controlling cyclin D1b were challenged...

Research Grants2

  1. Bis-phenol A: Signaling and Mitogenesis in the Prostate
    Karen Knudsen; Fiscal Year: 2006
    ..abstract_text> ..
  2. Role of BAF57 in AR control and prostate cancer growth
    Karen E Knudsen; Fiscal Year: 2010
    ..Together, these studies will reveal the efficacy of BAF57 as a therapeutic target in both early and late stage prostate cancer. ..